Sci-Tech Innovation 200 ETF Penghua(588240) up over 2.8%, biopharmaceuticals strongly rallying

The pharmaceutical sector surged in early trading. On the news front, there has been continuous progress in the innovative drug field. Hotgen Biotech announced that its subsidiary, ShunJing Pharmaceutical, has completed the first subject enrollment and dosing for the Phase II clinical study of its independently developed innovative drug SGC001 injection. As of March 21, the total outbound business development (BD) for Chinese innovative drugs this year has reached $57.1 billion, with an upfront payment of $3.3 billion and a total of 53 cases. This total package is equivalent to 41% of the entire year’s 2025 forecast and has already exceeded the total level of 2024.

Guotai Junan Securities pointed out that the current innovative drug BD transactions are intensively landing, and drug R&D innovation is recovering. The demand for Contract Research Organizations (CROs) is gradually recovering, and the year-on-year decline in revenue for related CRO listed companies has narrowed. Given the current recovery in clinical CRO order demand and gradual price improvement, we are optimistic about the marginal improvement in clinical CRO business. Among preclinical CROs, the price of experimental monkeys has gradually stabilized, and it is expected to steadily rise in the future. In terms of Site Management Organization (SMO) business, leading CRO companies are gradually expanding their SMO businesses, forming a strong competitive advantage.

As of March 27, 2026, at 13:19, the Shanghai Stock Exchange Sci-Tech Innovation Board 200 Index (000699) surged 3.18%, with component stocks Hotgen Biotech up 17.29%, Yinuosi up 13.02%, Tengjing Technology up 10.62%, and Dekeli, Warner Pharmaceuticals, and other stocks also rising. The Sci-Tech Innovation 200 ETF Penghua (588240) rose 2.89%, with the latest price reported at 1.53 yuan.

The Sci-Tech Innovation 200 ETF Penghua closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board 200 Index, which selects 200 securities with smaller market capitalization and better liquidity from the Sci-Tech Innovation Board of the Shanghai Stock Exchange as samples. The Shanghai Sci-Tech Innovation 200 Index, along with the Shanghai Sci-Tech Innovation Board 50 constituent index and the Shanghai Sci-Tech Innovation Board 100 index, forms the Shanghai Sci-Tech Innovation Board scale index series, reflecting the overall performance of securities of listed companies on the Sci-Tech Innovation Board across different market capitalization scales.

Data shows that as of February 27, 2026, the top ten weight stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board 200 Index (000699) are Zhenlei Technology, Juguang Technology, Purun Co., Jingzhida, Changguang Huaxin, Xinghuan Technology, Tengjing Technology, Xinqi Weizhuang, Jieput, and Dekeli, with the top ten weight stocks accounting for a total of 16.78%.

Sci-Tech Innovation 200 ETF Penghua (588240), off-market connection (A: 023926; C: 023927).

Massive information and precise interpretations are all available on the Sina Finance APP.